Cancer care is witnessing transformative advancements, driven by innovative technologies and strategic collaborations. In 2024, several significant initiatives have been launched to enhance precision treatment, improve training for medical professionals, and expand access to cutting-edge therapies.
The global radiation therapy market is experiencing substantial growth, driven by the increasing incidence of cancer, particularly in developing and underdeveloped regions. The market size was estimated at US$ 7.44 billion in 2024, grew to US$ 7.86 billion in 2025, and is projected to reach approximately US$ 12.93 billion by 2034. With a CAGR of 5.73% from 2025 to 2034, this expansion highlights the rising demand for advanced radiotherapy solutions and the integration of innovative treatment methods.
Get All the Details in Our Solution – Download Brochure @ https://www.towardshealthcare.com/download-brochure/5415
In July 2024, Mr. Dinesh Madhavan, President of Group Oncology and International at Apollo Hospital Enterprises Ltd, highlighted the impact of emerging technologies in cancer care. He emphasized how innovation paves the way for highly individualized and effective treatments.
A major step in this direction is the collaboration between Accuracy and Apollo Cancer Centres to introduce the Robotic Stereotactic Radiotherapy Program. This initiative aims to bolster training facilities across the ASEAN region, equipping physicists, therapists, and oncologists with the expertise required to leverage the latest CyberKnife technologies. By enhancing precision and efficiency in radiotherapy, the program seeks to elevate treatment standards and patient outcomes.
In October 2024, Leo Cancer Care unveiled UPLIFT, a multi-million-euro initiative dedicated to research and training in upright radiation therapy. This ambitious project is designed to integrate upright radiotherapy into mainstream radiation treatment, with a strong focus on making radiotherapy more sustainable, accessible, and patient-centric.
Upright radiotherapy has the potential to revolutionize cancer treatment by offering increased comfort and precision for patients, particularly those with mobility challenges. The UPLIFT initiative will support clinical advancements and provide training programs to ensure widespread adoption of this cutting-edge approach.
In May 2024, Novartis announced the acquisition of Mariana Oncology, a preclinical-stage biotechnology company based in Watertown, Massachusetts. Mariana Oncology specializes in developing radioligand therapeutics (RLTs), which offer a targeted approach to treating cancers with significant unmet needs.
This acquisition underscores Novartis’ commitment to expanding its portfolio in precision oncology. Radioligand therapies work by delivering radioactive isotopes directly to cancer cells, minimizing damage to healthy tissues and improving treatment efficacy. The integration of Mariana Oncology’s expertise is expected to accelerate advancements in RLTs, providing new hope for patients with complex cancer conditions.
Our Table of Content (TOC) covers key healthcare market segments, materials, technologies and trends—helping you navigate market shifts and make informed decisions: https://www.towardshealthcare.com/table-of-content/radiation-therapy-market-sizing
Invest in Our Premium Strategic Solution @ https://www.towardshealthcare.com/price/5415
We’ve prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com
Web: https://www.towardshealthcare.com
Visit Dental Specifics: https://www.towardsdental.com
Get the latest insights on industry segmentation with our Annual Membership: Get a Subscription
For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare
The global digital health market is witnessing a steady rise and much of it is driven by the increasing number… Read More
In 2025, North America emerged as the clear frontrunner in the healthcare Contract Research Organization (CRO) market and it’s easy… Read More
Powering the Future of Cell and Gene Therapy Virocell Biologics, a leading name in vector manufacturing for cell and gene… Read More
A Big Leap Forward in PAH Care Pahr Therapeutics Inc. has raised $14 million in seed funding to accelerate its… Read More
Reimagining Immunology, Together In a groundbreaking partnership, Bristol Myers Squibb (BMS) and Bain Capital have come together to launch a… Read More
Genethon, a global leader in gene therapy for rare genetic diseases, has received the green light from the UK and… Read More